Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1018979 | 0.87 | CHRNA7 (0.44) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL1017495 | 0.86 | CHRNA7 (0.43) | CHRNA7CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1018872 | 0.86 | CHRNA7 (0.43) | CHRNA7CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1018662 | 0.86 | CHRNA7 (0.41) | CHRNA7CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL3084805 | 0.85 | CHRNA7 (0.46) | CHRNA7CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL3088178 | 0.85 | CHRNA7 (0.46) | CHRNA7CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1018721 | 0.85 | CHRNA7 (0.46) | CHRNA7CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1018551 | 0.83 | CHRNA7 (0.44) | CHRNA7CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1019786 | 0.83 | CHRNA7 (0.44) | CHRNA7CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1018506 | 0.82 | CHRNA7 (0.40) | CHRNA7CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802616-B1 | NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2011-01-12 | — | — | EP | claimed |
| US-7652010-B2 | Azabicyclic aryl derivatives and their medical use | NEUROSEARCH A/S (DK) | 2010-01-26 | — | — | US | claimed |
| US-20070299082-A1 | Novel Azabicyclic Aryl Derivatives and Their Medical Use | ANIONA APS (DK) | 2007-12-27 | — | — | US | claimed |
| EP-1802616-A1 | NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-07-04 | — | — | EP | claimed |
| WO-2006040352-A1 | NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-04-20 | — | — | WO | claimed |
| EP-1802616-B1 | NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2011-01-12 | — | — | EP | disclosed |
| US-7652010-B2 | Azabicyclic aryl derivatives and their medical use | NEUROSEARCH A/S (DK) | 2010-01-26 | — | — | US | disclosed |
| US-20070299082-A1 | Novel Azabicyclic Aryl Derivatives and Their Medical Use | ANIONA APS (DK) | 2007-12-27 | — | — | US | disclosed |
| EP-1802616-A1 | NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040352-A1 | NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299082-A1 | Novel Azabicyclic Aryl Derivatives and Their Medical Use | CHRNA6, CHRNA10, CHRNA5 | CHRNA7 6/4885CHRM2 19/4885CHRM1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.